Fecal calprotectin is a clinically relevant biomarker of mucosal healing in patients with quiescent ulcerative colitis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 31, Issue 1, 2016, Pages 93-98

  Yamaguchi, Sayaka ^a   Takeuchi, Yoshiaki ^a   Arai, Katsuhito ^a   Fukuda, Katsuyuki ^b   Kuroki, Yuichiro ^c   Asonuma, Kunio ^c   Takahashi, Hiroshi ^c   Saruta, Masayuki ^d   Yoshida, Hitoshi ^a  

^a SHOWA UNIVERSITY   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Biomarker; Fecal calprotectin; Mucosal healing; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; HEMOGLOBIN; SERUM ALBUMIN;

ADULT; ARTICLE; COLONOSCOPY; ENZYME IMMUNOASSAY; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; FLUORESCENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO ENDOSCOPIC SUBSCORE; MEASUREMENT ACCURACY; PREDICTIVE VALUE; PRIORITY JOURNAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; ULCER HEALING; ULCERATIVE COLITIS; CHEMISTRY; CLINICAL TRIAL; FECES; INTESTINE MUCOSA; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; BIOMARKERS; COLITIS, ULCERATIVE; COLONOSCOPY; FECES; FEMALE; HUMANS; INTESTINAL MUCOSA; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84956898661     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.13061     Document Type: Article

References (30)

1. Gomes P, Boulay C du, Smith CL, Holdstock G. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut 1986; 27: 92-5.
2. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 1357-63.
3. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Doboset GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am. J. Gastroenterol. 2008; 103: 162-9.
4. Hanai H, Takeuchi K, Iida T et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig. Dis. Sci. 2004; 49: 1438-43.
5. Xiang Y, Ouyang Q, Li GD, Xiao N. Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J. Gastroenterol. 2008; 14: 53-7.
6. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Renzulli P, Seibold F. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm. Bowel Dis. 2009; 15: 1851-8.
7. D'Haens G, Ferrante M, Vermeire S et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm. Bowel Dis. 2012; 18: 2218-24.
8. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterol. 2000; 119: 15-22.
9. Maiden L, Takeuchi K, Baur R et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm. Bowel Dis. 2008; 14: 1413-8.
10. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterol. 2007; 133: 412-22.
11. Ardizzone S, Cassinotti A, Duca P et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clin. Gastroenterol. Hepatol. 2011; 9: 483-9.
12. Colombel JF, Rutgeerts P, Reinisch W et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterol. 2011; 141: 1194-201.
13. Meucci G, Fasoli R, Saibeni S et al. Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. Inflamm. Bowel Dis. 2012; 18: 1006-10.
14. Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin. Gastroenterol. Hepatol. 2005; 3: 11-24.
15. Baars JE, Nuij VJ, Oldenburg B, Kuipers EJ, Van der Woude CJ. Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm. Bowel Dis. 2012; 18: 1634-40.
16. Rosenberg L, Lawlor GO, Zenlea T et al. Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission. Inflamm. Bowel Dis. 2013; 19: 779-84.
17. Osada T, Ohkusa T, Okayasu I et al. Correlations among total colonoscopic findings, clinical symptoms, and laboratory markers in ulcerative colitis. J. Gastroenterol. Hepatol. 2008; 23(Suppl 2): S262-7.
18. Lobaton T, Rodriguez-Moranta F, Lopez A, Sánchez E, Rodríguez-Alonso L, Guardiola J. A new rapid quantitative test for fecal calprotectin predicts endoscopic activity in ulcerative colitis. Inflamm. Bowel Dis. 2013; 19: 1034-42.
19. Kristensen V, Klepp P, Cvancarova M, Røseth A, Skar V, Moum B. Prediction of endoscopic disease activity in ulcerative colitis by two different assays for fecal calprotectin. J. Crohns Colitis 2014 (in press).
20. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study. N. Engl. J. Med. 1987; 317: 1625-9.
21. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
22. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 2012; 107: 1474-82.
23. Menees S, Higgins P, Korsnes S, Elta G. Does colonoscopy cause increased ulcerative colitis symptoms? Inflamm. Bowel Dis. 2007; 13: 12-8.
24. Sacco R, Tanaka T, Yamamoto T, Bresci G, Saniabadi AR. Adacolumn leucocytapheresis for ulcerative colitis: clinical and endoscopic features of responders and unresponders. Expert Rev. Gastroenterol. Hepatol. 2014; 27: 1-7.
25. Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H. Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs. World J. Gastroenterol. 2014; 20: 9699-715.
26. Labaere D Smismans A, Van Olmen A et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United Eur. Gastroenterol. J. 2014; 2: 30-7.
27. Robert ME, Skacel M, Ullman T, Bernstein CN, Easley K, Goldblum JR. Patterns of colonic involvement at initial presentation in ulcerative colitis. A retrospective study of 46 newly diagnosed cases. Am. J. Clin. Pathol. 2004; 122: 94-9.
28. Joo M, Odze RD. Rectal sparing and skip lesions in ulcerative colitis: a comparative study of endoscopic and histologic findings in patients who underwent proctocolectomy. Am. J. Surg. Pathol. 2010; 34: 689-96.
29. Osada T, Ohkusa T, Yokoyama T et al. Comparison of several activity indices for the evaluation of endoscopic activity in UC: inter- and intraobserver consistency. Inflamm. Bowel Dis. 2010; 16: 192-7.
30. Yamamoto T. The clinical value of fecal calprotectin and lactoferrin measurement in postoperative Crohn's disease. United Eur. Gastroenterol. J. 2015; 3: 5-10.